Transforming autoimmune care for Rx non-responders through personalized trials


Mymee is the first digital care solution for autoimmune patients with moderate to severe symptoms uncontrolled by Rx.
Mymee’s peer-reviewed solution supports autoimmune Rx non-responders and long COVID patients who struggle with significant symptoms including joint pain, fatigue and activity limitations despite prescription medications. Click here for a complete list of symptoms.
Patients receive personalized trial & care and support to safely identify hidden triggers in their exposome, lower health risks and reduce, predict and control their flares.
Patients taking 5 mean autoimmune Rx, who had co-morbidities and moderate to severe rheumatic symptoms at baseline achieved clinically meaningful HRQoL improvement in an average 17 weeks*
Validated in peer-reviewed study analyzing efficacy of personalized trials (n=202) among autoimmune disease and Long COVID patients published in RMD Open, May 2023.

Trigger identification: Over 100 unique triggers correlated to > 50 symptoms, including single triggers to ≥ 1 symptoms and complex combinations with a compounding effect.

>85% of symptomatic patients achieved HRQoL improvement. Weighted mean symptoms improvement at endpoint was >40%.

Autoimmune disease patients with joint pain were taking an average >5 medications at baseline, with 73% reporting at least one comorbidity.

Patients reporting most difficulty managing symptoms at baseline, reported most improvement at endpoint.

Patients' perceived ability to work with their doctor to manage symptoms improved by 98%.
* Sources: 1. Peer-reviewed study of personalized trials in autoimmune population, Rheumatic & Musculoskeletal Open Journal, May 2023; 2. Symptoms-59 survey, weighted mean change (n=182 personalized trials); 3. A Self-Evidence-Driven Personalized Trial and Care Program Correlates the Exposome to Persistent Autoimmune Rheumatic Symptoms and Improves Health-Related Quality of Life; (n=163 personalized trials); poster, IMF conference, 2023.
How do I know which of my patients may be a good candidate for a personalized trial & care program?
If your patient is taking 1 or more immunosuppressants plus other concomitant medications, and complaining of activity limitations and joint pain, swelling, fatigue, digestive issues or headaches, Mymee can help. Click here to learn more about who may benefit from personalized trials.
To learn more about Mymee’s personalized trial research, case studies or clinical validation, please complete the form below or contact us: research@mymee.com
Learn more about supporting your patients through personalized trials
Read on for additional articles and insights related to Mymee’s research and use of coach-led personalized trials to guide statistically significant improvements in quality of life.

.png)
RMD Open: Self-evidence based digital care program improves HRQoL in adults with a variety of autoimmune diseases and long COVID

Rheumatology Network: Self-Advocacy Platform Allows Patients with Autoimmune Diseases to Discover Triggers, Improve Disease Management

PR Newswire: New Real-world Study Demonstrates Connection Between
Long COVID and Rheumatic Autoimmune Disease Symptoms and Environmental Triggers
